Noted: WARF Therapeutics, unveiled last week at a meeting on campus, will help UW–Madison investigators deal with a difficult reality: Pharmaceutical companies are reluctant to license newly discovered biological entities (more commonly called “targets”), such as proteins or genes, that are instrumental in disease.
Read the full article at: https://news.wisc.edu/warf-bets-big-on-new-squad-of-drug-hunters/